Freddie Craig Stevens is a prominent inventor based in Indianapolis, IN (US), known for his significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, Stevens has made remarkable advancements in drug development and therapeutic applications.

Latest Patents

Among his latest patents is a TARP γ8 dependent AMPA receptor antagonist, which includes a detailed formula and its pharmaceutically acceptable salts. This invention outlines its uses and methods for preparation. Another notable patent involves pyrrolidine derivatives as histamine H3 receptor antagonists. This invention discloses novel compounds that exhibit histamine-H3 receptor antagonist or inverse agonist activity, along with methods and intermediates for their preparation. Additionally, it includes pharmaceutical compositions comprising these compounds and methods for treating obesity, cognitive deficiencies, narcolepsy, and other related diseases.

Career Highlights

Freddie Craig Stevens is currently associated with Eli Lilly and Company, a leading pharmaceutical firm. His work at Eli Lilly has allowed him to focus on innovative drug solutions that address various health challenges.

Collaborations

Stevens has collaborated with notable colleagues, including Cynthia Darshini Jesudason and Daniel Jon Sall, contributing to a dynamic research environment that fosters innovation.

Conclusion

Freddie Craig Stevens exemplifies the spirit of innovation in the pharmaceutical industry through his extensive patent portfolio and collaborative efforts. His work continues to impact the field significantly, paving the way for future advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.